NCT04956640 2025-09-25Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Eli Lilly and CompanyPhase 1/2 Recruiting540 enrolled
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn